ECOG- Frequently Asked Questions about the ECOG Clinical Trial for
People Newly Diagnosed with Multiple Myeloma (E4A03)
Follow the link below to view the handout answering frequently asked
questions about the E4A03 ECOG Clinical Trial for People Newly Diagnosed with Multiple Myeloma. This is a "Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therapy for non-Responders".
The document is in Adobe Acrobat format. If you do not already
have Adobe Acrobat Reader running on your computer you can
download this software free of charge from the Adobe web site.
Next topic
How to contact ECOG
All contents copyright © 2001 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: March 11, 2005
